{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:49:05Z","timestamp":1792558145539,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06770-2","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:19:45Z","timestamp":1770268785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (>\u200970 y) with follicular lymphoma: a tertiary academic center experience"],"prefix":"10.1007","volume":"105","author":[{"given":"Mattia","family":"D\u2019Antiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Danesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Scapinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angotzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"6770_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","volume":"34","author":"JR Cerhan","year":"2020","unstructured":"Cerhan JR (2020) Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am 34:631\u2013646","journal-title":"Hematol Oncol Clin North Am"},{"key":"6770_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"6770_CR3","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u201352","journal-title":"Blood"},{"key":"6770_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331\u201344","journal-title":"N Engl J Med"},{"key":"6770_CR5","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/bloodadvances.2020002724","volume":"5","author":"C Casulo","year":"2021","unstructured":"Casulo C, Dixon JG, Ou FS et al (2021) Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv 5:1737\u20131745","journal-title":"Blood Adv"},{"key":"6770_CR6","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.24921","volume":"93","author":"AJ Olszewski","year":"2018","unstructured":"Olszewski AJ, Reagan JL, Castillo JJ (2018) Late infections and secondary malignancies after bendamustine\/rituximab or R-CHOP\/R-CVP chemotherapy for B-cell lymphomas. Am J Hematol 93:E1\u20133","journal-title":"Am J Hematol"},{"key":"6770_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/cid\/ciy458","volume":"68","author":"M Fung","year":"2019","unstructured":"Fung M, Jacobsen E, Freedman A et al (2019) Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to Bendamustine. Clin Infect Dis 68:247\u2013255","journal-title":"Clin Infect Dis"},{"key":"6770_CR8","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1002\/cncr.28350","volume":"119","author":"P Martin","year":"2013","unstructured":"Martin P, Byrtek M, Dawson K et al (2013) Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the united states: results of the National lymphocare study. Cancer 119:4129\u20134136","journal-title":"Cancer"},{"key":"6770_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00277-021-04576-y","volume":"101","author":"Y Masamoto","year":"2022","unstructured":"Masamoto Y, Shimura A, Kurokawa M (2022) Reduced bendamustine for elderly patients with follicular lymphoma. Ann Hematol 101:713\u2013715","journal-title":"Ann Hematol"},{"key":"6770_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00277-022-05037-w","volume":"102","author":"Y Masamoto","year":"2023","unstructured":"Masamoto Y, Shimura A, Honda A et al (2023) Obinutuzumab and reduced Bendamustine is effective for elderly patients with follicular lymphoma. Ann Hematol 102:243\u2013244","journal-title":"Ann Hematol"},{"key":"6770_CR11","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/ijc.34412","volume":"152","author":"R Kotchetkov","year":"2023","unstructured":"Kotchetkov R, Drennan IR, Susman D et al (2023) Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma in elderly: a single center observational study. Int J Cancer 152:1884\u201393","journal-title":"Int J Cancer"},{"issue":"12","key":"6770_CR12","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1002\/cncr.11846","volume":"98","author":"KW Lee","year":"2003","unstructured":"Lee KW, Kim DY, Yun T et al (2003) Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 98(12):2651\u20132656","journal-title":"Cancer"},{"key":"6770_CR13","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Tobinai K, Shibata T et al (2011) Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J Clin Oncol 29:3990\u20133998","journal-title":"J Clin Oncol"},{"key":"6770_CR14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2019) First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with Bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37:984\u2013991","journal-title":"J Clin Oncol"},{"issue":"8","key":"6770_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09743-9","volume":"33","author":"C Giordano","year":"2025","unstructured":"Giordano C, Picardi M, Vincenzi A et al (2025) Long-acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine-treated patients with indolent B cell non-Hodgkin lymphoma: a multicentric real-life experience. Support Care Cancer 33(8):691. https:\/\/doi.org\/10.1007\/s00520-025-09743-9","journal-title":"Support Care Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06770-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:05:34Z","timestamp":1771949134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06770-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6770"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06770-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants followed the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Authors declare no conflict of interest relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"90"}}